Keybank National Association OH Cuts Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Keybank National Association OH trimmed its holdings in shares of Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 12.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,966 shares of the company’s stock after selling 422 shares during the period. Keybank National Association OH’s holdings in Omnicell were worth $337,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in OMCL. CWM LLC raised its stake in Omnicell by 16.9% in the second quarter. CWM LLC now owns 637 shares of the company’s stock worth $72,000 after buying an additional 92 shares in the last quarter. Archer Investment Corp raised its stake in Omnicell by 27.1% in the second quarter. Archer Investment Corp now owns 469 shares of the company’s stock worth $53,000 after buying an additional 100 shares in the last quarter. Raymond James Trust N.A. raised its stake in Omnicell by 2.9% in the second quarter. Raymond James Trust N.A. now owns 3,993 shares of the company’s stock worth $455,000 after buying an additional 112 shares in the last quarter. Torray LLC increased its stake in shares of Omnicell by 1.2% during the second quarter. Torray LLC now owns 9,523 shares of the company’s stock valued at $1,083,000 after purchasing an additional 112 shares in the last quarter. Finally, Harbor Investment Advisory LLC increased its stake in shares of Omnicell by 26.1% during the second quarter. Harbor Investment Advisory LLC now owns 604 shares of the company’s stock valued at $69,000 after purchasing an additional 125 shares in the last quarter.

Omnicell Trading Up 4.2 %

Shares of OMCL stock opened at $52.61 on Friday. Omnicell, Inc. has a 12-month low of $46.19 and a 12-month high of $187.29. The company has a current ratio of 2.25, a quick ratio of 1.86 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $80.34 and its 200 day moving average is $100.34. The stock has a market capitalization of $2.33 billion, a P/E ratio of 51.58, a P/E/G ratio of 1.51 and a beta of 1.01.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on OMCL shares. StockNews.com started coverage on shares of Omnicell in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Benchmark downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, November 3rd. Craig Hallum decreased their target price on shares of Omnicell from $185.00 to $75.00 in a research note on Thursday, November 3rd. Bank of America began coverage on shares of Omnicell in a research note on Friday, September 9th. They set a “buy” rating and a $120.00 target price for the company. Finally, BTIG Research cut their price target on shares of Omnicell from $160.00 to $75.00 and set a “buy” rating on the stock in a report on Thursday, November 3rd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $85.63.

Insider Transactions at Omnicell

In other news, CEO Randall A. Lipps sold 13,000 shares of Omnicell stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total transaction of $1,443,520.00. Following the transaction, the chief executive officer now owns 302,049 shares in the company, valued at approximately $33,539,520.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Peter J. Kuipers sold 11,000 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $105.93, for a total transaction of $1,165,230.00. Following the sale, the chief financial officer now directly owns 61,326 shares in the company, valued at approximately $6,496,263.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Randall A. Lipps sold 13,000 shares of the firm’s stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total transaction of $1,443,520.00. Following the sale, the chief executive officer now owns 302,049 shares in the company, valued at $33,539,520.96. The disclosure for this sale can be found here. Insiders have sold 39,500 shares of company stock worth $4,287,245 in the last 90 days. 2.76% of the stock is currently owned by insiders.

About Omnicell

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Read More

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCLGet Rating).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.